Abstract:Silymarin, a characterized extract of the seeds of milk thistle (Silybum marianum), suppresses cellular inflammation. To define how this occurs, transcriptional profiling, metabolomics, and signaling studies were performed in human liver and T cell lines. Cellular stress and metabolic pathways were modulated within 4 h of silymarin treatment: activation of Activating Transcription Factor 4 (ATF-4) and adenosine monophosphate protein kinase (AMPK) and inhibition of mammalian target of rapamycin (mTOR) signaling… Show more
“…Regardless, the majority of the top most differentially expressed genes were down‐regulated in SIL‐treated mice, suggesting an inhibitory trend. Importantly, the results of pathway analysis suggest that SIL may exert anti‐inflammatory effects through upstream inhibition of cytokine signalling as well as TNF‐α and NF κ B‐associated transcriptional regulation, which is consistent with previous studies demonstrating suppression of cell growth and metabolism in peripheral blood mononuclear cells and inhibition of TNF‐α‐ and NF κ B‐mediated pro‐inflammatory gene expression in hepatic and other cell types . While further experiments are needed to reveal the nature of the observed anti‐inflammatory gene expression and whether the human hepatocytes were responding to the SIL directly and/or via signals from the mouse hepatic nonparenchymal cells, it is interesting that significant anti‐HCV effects of SIL were observed in vivo in the absence of a secondary adaptive immune response and perhaps explains why SIL has been effective in HCV‐infected patients post‐transplant .…”
Background/Aim
Legalon SIL (SIL) is a chemically hydrophilized version of silibinin, an extract of milk thistle (Silybum marianum) seeds that has exhibited hepatoprotective and antiviral effectiveness against hepatitis C virus (HCV) in patients leading to viral clearance in combination with ribavirin. To elucidate the incompletely understood mode of action of SIL against HCV, mathematical modeling of HCV kinetics and human hepatocyte gene expression studies were performed in uPA-SCID-chimeric mice with humanized livers.
Methods
Chronically HCV-infected mice (n=15) were treated for 14 days with daily intravenous SIL at 469, 265 or 61.5 mg/kg. Serum HCV and human albumin (hAlb) were measured frequently and liver HCV RNA was analyzed at days 3 and 14. Microarray analysis of human hepatocyte gene expression was performed at days 0, 3, and 14 of treatment.
Results
While hAlb remained constant, a biphasic viral decline in serum was observed consisting of a rapid 1st phase followed by a 2nd slower phase (or plateau with the two lower SIL dosings). SIL effectiveness in blocking viral production was similar among dosing groups (median ε=77%). However, the rate of HCV-infected hepatocyte decline, δ, was dose-dependent. Intracellular HCV RNA levels correlated (r=0.66, P=.01) with serum HCV RNA. Pathway analysis revealed increased anti-inflammatory and anti-proliferative gene expression in human hepatocytes in SIL-treated mice.
Conclusions
The results suggest that SIL could lead to a continuous 2nd phase viral decline, i.e., potentially viral clearance, in the absence of adaptive immune response along with increased anti-inflammatory and anti-proliferative gene expression in human hepatocytes.
“…Regardless, the majority of the top most differentially expressed genes were down‐regulated in SIL‐treated mice, suggesting an inhibitory trend. Importantly, the results of pathway analysis suggest that SIL may exert anti‐inflammatory effects through upstream inhibition of cytokine signalling as well as TNF‐α and NF κ B‐associated transcriptional regulation, which is consistent with previous studies demonstrating suppression of cell growth and metabolism in peripheral blood mononuclear cells and inhibition of TNF‐α‐ and NF κ B‐mediated pro‐inflammatory gene expression in hepatic and other cell types . While further experiments are needed to reveal the nature of the observed anti‐inflammatory gene expression and whether the human hepatocytes were responding to the SIL directly and/or via signals from the mouse hepatic nonparenchymal cells, it is interesting that significant anti‐HCV effects of SIL were observed in vivo in the absence of a secondary adaptive immune response and perhaps explains why SIL has been effective in HCV‐infected patients post‐transplant .…”
Background/Aim
Legalon SIL (SIL) is a chemically hydrophilized version of silibinin, an extract of milk thistle (Silybum marianum) seeds that has exhibited hepatoprotective and antiviral effectiveness against hepatitis C virus (HCV) in patients leading to viral clearance in combination with ribavirin. To elucidate the incompletely understood mode of action of SIL against HCV, mathematical modeling of HCV kinetics and human hepatocyte gene expression studies were performed in uPA-SCID-chimeric mice with humanized livers.
Methods
Chronically HCV-infected mice (n=15) were treated for 14 days with daily intravenous SIL at 469, 265 or 61.5 mg/kg. Serum HCV and human albumin (hAlb) were measured frequently and liver HCV RNA was analyzed at days 3 and 14. Microarray analysis of human hepatocyte gene expression was performed at days 0, 3, and 14 of treatment.
Results
While hAlb remained constant, a biphasic viral decline in serum was observed consisting of a rapid 1st phase followed by a 2nd slower phase (or plateau with the two lower SIL dosings). SIL effectiveness in blocking viral production was similar among dosing groups (median ε=77%). However, the rate of HCV-infected hepatocyte decline, δ, was dose-dependent. Intracellular HCV RNA levels correlated (r=0.66, P=.01) with serum HCV RNA. Pathway analysis revealed increased anti-inflammatory and anti-proliferative gene expression in human hepatocytes in SIL-treated mice.
Conclusions
The results suggest that SIL could lead to a continuous 2nd phase viral decline, i.e., potentially viral clearance, in the absence of adaptive immune response along with increased anti-inflammatory and anti-proliferative gene expression in human hepatocytes.
“…For example, silymarin effectively suppressed tumorigenesis via improving oxidative stress and deregulating activation of inflammatory mediators (Wu et al 2008;Toyoda-Hokaiwado et al 2011). Silybin inhibited lipopolysaccharide (LPS)-induced morphological changes and the production of pro-inflammatory cytokines through inhibiting NF-jB signaling pathway Lovelace et al 2015). In addition, silymarin can improve fructose-induced metabolic abnormalities in rat (Prakash et al 2014).…”
Context: Silymarin is the main flavonoid extracted from milk thistle, which has been used to treat liver diseases. Objective: The in vivo effect of silymarin on HFD-induced insulin resistance and fatty liver in mice was studied. Materials and methods: Male C57BL/6 mice were fed with high-fat diet (HFD) to induce obesity and insulin resistance and treated with 30, 60 mg/kg silymarin for 18 days. Food intake, body weight and the content/histology of epididymal fat and liver tissue were examined; the content of lipids, AST, ALT and inflammatory cytokines in serum were estimated. Results: Administration of silymarin caused bodyweight loss in diet induced obesity (DIO) mice (HFD group: 47.7 g, 60 mg/kg group: 43.0 g) while the food intake remain unchanged. Silymarin (60 mg/kg) significantly reduced the epididymal fat mass (from 1.75 g to 1.12 g). Elevated plasma lipids (TC 6.1 mM, TG 1.3 mM, LDL 1.2 mM) in DIO mice were all suppressed by silymarin (TC 4.5 mM, TG 0.89 mM, LDL 0.9 mM), as well as insulin (5.1 ng/ml in HFD group to 2.0 ng/ml (60 mg/kg silymarin). Examination of cytokine levels (TNF-a, IL-1b and IL-6) in each group proved that silymarin treatment significantly decreased inflammation in DIO mice. Finally, silymarin effectively protected liver from HFD-induced injury as evidenced by decreasing histological damage and reducing ALT and AST levels, as follows: ALT; 47.4 U/L in HFD group to 28.4 U/L (60 mg/kg silymarin); AST; 150.1 U/L in HFD group to 88.1 U/L (60 mg/kg silymarin) in serum. Discussion and conclusion: Our results suggested that silymarin-induced alleviation of inflammatory response could be a mechanism responsible for its benefits against liver damage and insulin resistance.
ARTICLE HISTORY
“…This supply, in turn, has assisted with the examination of the cytoprotective properties of the milk thistle compounds, where they have demonstrated activity in inhibiting virus infection, preventing oxidative stress, and modulating cellular metabolic and inflammatory status [5–7]. For effective studies of the biological activity of milk thistle preparations, both in vitro and in vivo, knowledge of the quantity and identity of bioactive constituents in study material is needed.…”
Validated methods are needed for the analysis of natural product secondary metabolites. These methods are particularly important to translate in vitro observations to in vivo studies. Herein, a method is reported for the analysis of the key secondary metabolites, a series of flavonolignans and a flavonoid, from an extract prepared from the seeds of milk thistle [Silybum marianum (L.) Gaertn. (Asteraceae)]. This report represents the first UHPLC MS-MS method validated for quantitative analysis of these compounds. The method takes advantage of the excellent resolution achievable with UHPLC to provide a complete analysis in less than 7 min. The method is validated using both UV and MS detectors, making it applicable in laboratories with different types of analytical instrumentation available. Lower limits of quantitation achieved with this method range from 0.0400 μM to 0.160 μM with UV and from 0.0800 μM to 0.160 μM with MS. The new method is employed to evaluate variability in constituent composition in various commercial S. marianum extracts, and to show that storage of the milk thistle compounds in DMSO leads to degradation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.